Drug Trial Radar · NCT06681493
A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects
Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Oct 12, 2022
Primary completion
Apr 14, 2023
Study completion Sep 22, 2023
Sponsor
- Lead sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part A Primary objective: • To evaluate the safety, tolerability, and pharmacokinetic profile of a single dose of YZJ-4729 tartrate injection. Secondary objectives: * To investigate the PK/PD profile of YZJ-4729 tartrate injection administered as a single dose; * To investigate the metabolic transformation characteristics of YZJ-4729 tartrate; * To assess the relationship between plasma concentrations and change in QT interval (C-QT) and the effect on QT interval in subjects after a single dose of YZJ-4729 tartrate injection. Part B Primary objective: • To evaluate the safety, tolerability and pharmacokinetic profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates . Secondary objectives: • To investigate the PK/PD profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates.
Conditions
- Postoperative Analgesia
Interventions
YZJ-4729 Tartrate injectionDrug
Infusion, QD
YZJ-4729 simulated injectionDrug
Infusion, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
- Incidence of participants with clinical laboratory abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
- Incidence of participants with vital signs abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
- Incidence of participants with physical exam abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
- CmaxTime frame: Pre-dose to 72 hours post-dose
- AUCinfTime frame: Pre-dose to 72 hours post-dose
- AUC0-24hTime frame: Pre-dose to 72 hours post-dose
- AUC0-tTime frame: Pre-dose to 72 hours post-dose
- t1/2zTime frame: Pre-dose to 72 hours post-dose
- TmaxTime frame: Pre-dose to 72 hours post-dose
- CLTime frame: Pre-dose to 72 hours post-dose
- VzTime frame: Pre-dose to 72 hours post-dose
- MRTTime frame: Pre-dose to 72 hours post-dose
- Ae0-tTime frame: Pre-dose to 72 hours post-dose
- Cumulative excretion percentage of drug through urine and fecesTime frame: Pre-dose to 72 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Third Hospital, Central South University
Changsha, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.